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This is a new template.
CAP Approved
Diffuse Large B-Cell Lymphoma • Biomarkers Completion of the template is the responsibility of the laboratory performing the biomarker testing and/or providing the interpretation. When both testing and interpretation are performed elsewhere (eg, a reference laboratory), synoptic reporting of the results by the laboratory submitting the tissue for testing is also encouraged to ensure that all information is included in the patient's medical record and thus readily available to the treating clinical team.
DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED (NOS)
Select a single response unless otherwise indicated.
Note: Use of this template is optional. 
+ SPECIMEN TYPE
Explanatory Notes
A. Protein Expression
The antibodies listed are included in the template because they have therapeutic or prognostic significance.
CD20 assessment is mandatory for therapeutic planning because the standard therapy for diffuse large B-cell lymphoma (DLBCL) patients is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). 1 Knowledge of CD20 expression is therefore recommended as a justification for using rituximab.
CD30 assessment is recommended because of the potential utility of the anti-CD30 antibody drug conjugate, brentuximab vedotin. Approximately 10% to 15% of DLBCL cases express CD30, and these patients may be eligible for this agent if they fail standard therapy. 2 CD5 assessment is thought to be of prognostic value because a small subset (5%-10%) of DLBCL cases.
Patients with CD5+ DLBCL have a more aggressive clinical course. These patients tend to be older and have elevated serum LDH levels, poorer performance status, and a higher frequency of central nervous system involvement. 3 MYC assessment by immunohistochemistry (IHC) is of prognostic value and needs to be evaluated in conjunction with conventional cytogenetic analysis or FISH to assess chromosome locus 8q24/MYC rearrangements. Approximately 10% of DLBCL cases carry MYC translocations, and up to 30% to 40% of cases overexpress MYC by IHC, with positivity defined in various studies as >40% or >50% positive cells. Therefore, MYC can be overexpressed via mechanisms other than translocation. 4, 5 The combination of MYC and BCL2 and/or BCL6 gene rearrangements as shown by conventional cytogenetic or FISH analysis is known as double (or triple) hit lymphoma. Patients with this combination of abnormalities have a poor prognosis. 6 MYC positivity by IHC may be useful as a screen for MYC translocations as it is rare for a translocation positive case to be negative for MYC by IHC. MYC expression combined with BCL2 overexpression is also associated with a poorer prognosis (so-called IHC double hit lymphoma).
BCL2 assessment also has prognostic value and needs to be evaluated in conjunction with conventional cytogenetic analysis or FISH to assess chromosome locus 8q24/MYC rearrangements. In patients treated with CHOP, BCL2 overexpression correlates with poorer prognosis in the germinal center type of DLBCL. 7 BCL2 overexpression combined with MYC overexpression correlates with a poorer prognosis (IHC double hit lymphoma).
B. Fluorescence In Situ Hybridization (FISH)
Recent studies have demonstrated that DLBCL with rearrangements of MYC and BCL2 or BCL6 comprise a distinct subgroup of cases, often termed double hit lymphomas, characterized by overlapping morphologic features with Burkitt lymphoma and a more aggressive clinical course. [8] [9] [10] [11] C. Subtyping Studies have shown there are prognostic differences in DLBCL that are germinal center derived (GC) versus non-germinal center derived (NGC). Several methodologies have been proposed for predicting GC versus NGC derivation. 12 In general, DLBCL of GC type is associated with a better prognosis. The most commonly applied immunohistochemical methodologies, which serve as a substitute for gene expression arrays (a gold standard for GC versus NGC), are Hans classifier, 13 Choi classifier, 14 
